Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-08-28
1995-09-05
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435974, 436 63, 436501, 514 2, 514 11, 514 19, 530300, 530317, 530331, 548537, A61K 3702, G01N 33566, G01N 33569
Patent
active
054479150
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy- termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to the inactivation of the human immunodeficiency virus and inhibition of infection of human cells in vivo and in vitro with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
2. Background of the Related Art
The use of peptides having antiviral properties is known in the art. [See, Ringrose, Biochem. Soc. Trans. 11:804-808 (1983) for a review].
Miller et al., Applied Microbiol. 16: 1489-1496 (1967) describe the use of N-carbobenzoxy-derivatives of (D)-Phe-(D)-Phe, (L)-Phe-nitro-Arg, (D)-Phe-(D)-Phe-nitro-Arg, (D)-Phe-(D)-Met, (D)-Phe-Ala and (D)-Phe-S-benzyl-Cys to inhibit herpesvirus and measles virus infections in vivo and in vitro. These peptides were inactive against a wide variety of other viruses tested.
Mathur et al., Ind. J. Exp. Biol. 20:227-229 (1982) disclose the antiviral activity of poly(.alpha.-L-Lys) and poly(.epsilon.-L-Lys) against a number of double stranded RNA viruses in vivo, mediated by the induction of the antiviral protein interferon.
Konopinska et al., Int. J. Peptide Protein Res. 22: 223-230 (1983) disclose the antiviral activity of three tuftsin analogs (Thr-Lys-Pro-Lys-Thr-Lys-Pro-Lys, (Seq. ID. No.:1) Thr-Lys-Pro-Lys-Thr-Lys-Pro-Arg, (Seq. ID. No:2) and Ala-Lys-Thr-Lys-Pro-Arg-Gln-Gln) (Seq. ID. No:3) against murine sarcoma virus infection in vitro.
Pert et al., Proc. Natl. Acad. Sci. USA 83:9254-9258 (1986) disclose that the octapeptide Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (Seq. ID. No:4) displays antiviral activity against human immunodeficiency virus (HIV-1) in vitro.
Dietrich et al., Int. J. Immunopharmac. 8: 931-942 (1986) teach the use of N-acetyl-muramyl-(L)-alanyl-(D)-isoglutaryl-(L)-alanine-2-(1',2'-dipalmito yl-sn-glycero-3'hydroxyphosphoryloxy)ethylamide sodium salt for prophylactic treatment of animals to prevent infection by influenza virus types A and B, parainfluenza virus 1 and herpes simplex virus types 1 and 2. This compound had no antiviral effect in vitro, however.
Daher et al., J. Virol. 60: 1068-1074 (1986) disclose the discovery of a naturally-occurring peptide of sequence ##STR1## derived from human neutrophil cells that inhibits infection of human cells by herpes simplex virus 1 and 2, cytomegalovirus, vesicular stomatitis virus and influenza virus A in vitro.
Docherty et al., Antimicrob. Agents and Chemother. 31: 1562-1566 (1987) teach the use of synthetic polymers of histidine (His.sub.24, His.sub.64, and His.sub.75) in vitro to effect the irreversible inhibition of infection of human cells with herpes simplex virus.
Lobl et al., Int. J. Protein Res. 32:326-330 (1988) teach the use of N-carbobenzoxy-(D)-Phe-Leu-Gly-(D)-Leu-(D)-Leu and N-carbobenzoxy-(D)-Phe-Leu-Gly-(D)-Leu-(D)-Leu-Gly to inhibit measles virus infection in vitro.
Naruse et al., J. Antibiotics 42:837-845 (1989) teach the use of a naturally-occurring peptide derived from Streptoverticillium cinnamoneum containing four unusual amino acids that displays antiviral activity against herpes simplex virus in vitro.
Srinivas et al., Virology 176:48-57 (1990) disclose the use of two synthetic peptides ##STR2## homologous to a region of the human apolipoprotein A-1 sequence, to inhibit infection and viral spread of herpes simplex virus 1 in vitro.
BJorck et al., J. Vir. 64: 941-943 (1990) teach that the synthetic peptide N-benzoxycarbonyl-leucylvalylglycine diazomethylketone (Z-LVG-CHN.sub.2) blocks the growth of herpes simplex virus but not poliovirus in vitro.
Inocencio et al., Med. Microbiol. Immunol. 179:87-94 (1990) disclose that the synthetic peptide Z-(D)-Phe
REFERENCES:
patent: 3705887 (1972-12-01), Wieland et al.
patent: 4954510 (1990-09-01), Tsuroka et al.
patent: 5023338 (1991-06-01), Ocaln et al.
patent: 5091366 (1992-02-01), Nutt et al.
patent: 5115098 (1992-05-01), Burakoff et al.
patent: 5215966 (1993-06-01), Holzemann et al.
Methoden Der Organischen Chemie (Houben-Weyl), published 1974, Band XV12, Synthese Von Peptiden Teil II, p. 328.
J. Med. Chemistry, vol. 11, issued 1968, Nicolaides et al, "Potential antiviral agents . . . ", pp. 74-79.
The Lancet, vol. 335, issued May 12, 1990, pp. 1128-1130.
Biochim, Biophys. Acta, vol. 989, issued 1989, Kieber-Emmons et al, "The gp120-CD4 interface . . . ", pp. 281-300.
Miller et al., 1968, Applied Microbiol. 16:1489-1496 (1968).
Mathur et al., 1982, Ind. J. Exp. Biol. 20:227-229 (1982).
Ringrose, 1983, Biochem. Soc. Trans. 11:804-808.
Konopinska et al., 1983, Int. J. Peptide Protein Res. 22:223-230.
Pert et al., 1986, Proc. Natl. Acad. Sci. USA 83:9254-9258.
Dietrich et al., 1986, Int. J. Immunopharmac. 8:931-942.
Daher et al., 1986, J. Virol. 60:1068-1074.
Smith et al., 1987, Science 238:1704-1707.
Docherty et al., 1987, Antimicrob. Agents and Chemother. 31:1562-1566.
Fauci, 1988, Science 239:617-622.
Fisher et al, 1988, Nature 331:76-78.
Hussey et al., 1988, Nature 331:78-81.
Deen et al., 1988, Nature 331:82-84.
Traunecker et al, 1988, Nature 331:84-86.
Jameson et al., 1988, Science 240:1335-1339.
Lifson et al, 1988, Science 241:712-716.
Lobl et al., 1988, Int. J. Protein Res. 32:326-330.
Naruse et al., 1989, J. Antibiotics 42:837-845.
Nara et al., 1989, Proc. Natl. Acad. Sci. USA 86:7139-7143.
Bowman et al., 1990, Proc. Natl. Acad. Sci. USA 87:9052-9056.
Finberg et al., 1990, Science 249:287-291.
Srinivas et al., 1990, Virology 176:48-57.
Bjorck et al., 1990, J. Vir. 64:941-943.
Inocencio et al, 1990, Med. Microbiol. Immunol. 179:87-94.
Burakoff Steven
Schreiber Stuart
Dana-Farber Cancer Institute Inc.
President and Fellows of Harvard College
Russel Jeffrey E.
LandOfFree
Terminally blocked antiviral peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Terminally blocked antiviral peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Terminally blocked antiviral peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-472807